CD8A and neoplasm: mJX-594 treatment increased OVA-specific CD8+ T cell expression, as well as VACV-specific CD8+ T cell expression, more than 10-fold in terms of the percentage and 30–50-fold in terms of the number of cells per milligram of tumor tissue, compared to vehicle treatment (Figure 3A–C).